Century Therapeutics, Inc.
NASDAQ:IPSC · NASDAQ Global Select
+$0.01 today
Vol 0.79M · Avg 1.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-6.0%
avg 13.0%
ROIC
-7.2%
avg -33.7%
ROA
-4.3%
avg -63.8%
Analysis
ROA is currently the strongest return metric at -4.3% versus its period average of -63.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brent Pfeiffenberger | President, Chief Executive Officer & Chairman | $971,732.00 | — | 48 | $3.68M | 4.25% |
Gregory Russotti | Chief Technology & Manufacturing Officer | $789,960.00 | — | 59 | $514,903.00 | 0.59% |
Chad A. Cowan | Chief Scientific Officer | $760,539.00 | — | 54 | $1.18M | 1.36% |
Krista Kauppinen | VP, General Counsel & Head of Intellectual Property | — | — | — | — | — |
Michael Naso | Senior Vice President of Cell Engineering | — | — | — | $253,533.00 | 0.29% |
Megan Bilson | Chief People Officer | — | — | — | — | — |
Douglas Carr | Senior VP of Finance & Operations, Principal Financial Officer and Secretary | — | — | — | $506,748.00 | 0.59% |
Elizabeth Devlin | Vice President & Head of Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$96,933.20
Sells
16
$66,551.63
Net Sentiment
+$30,381.57
Net buying
Most Active
Carr Douglas
8 transactions
1–10 of 19
Analysis
Insiders reported 3 buys worth $96,933.20 and 16 sells worth $66,551.63 over the last 12 months. That adds up to net buying of $30,381.57. Carr Douglas was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +66.0% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +66.0% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$215.30M
Equillium, Inc.
NASDAQ:EQ
$99.82M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Cue Biopharma, Inc.
NASDAQ:CUE
$64.46M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
Telomir Pharmaceuticals, Inc. Common Stock
TELO
$43.32M
Genenta Science S.p.A.
GNTA
$35.80M
Senti Biosciences, Inc.
SNTI
$25.24M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
Who manages IPSC?
Century Therapeutics, Inc. (IPSC) lists 8 active executives. The top listed executive is Chad A. Cowan, Chief Scientific Officer.
Are IPSC insiders buying or selling?
Recent insider activity shows net buying of $6.18M.
Explore More
Continue the stock analysis
Jump to another research area for this company.